TRIB NASDAQ
Trinity Biotech plc
1W: -15.8%
1M: -40.7%
3M: +1301.5%
YTD: +662.5%
1Y: +457.8%
3Y: -68.0%
5Y: -89.6%
$5.69
-0.63 (-9.97%)
Weekly Expected Move ±7.9%
$5
$5
$6
$6
$7
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$62M
+8.3% ▲
5Y CAGR: -7.4%
Gross Profit
$21M
+10.2% ▲
5Y CAGR: -10.9%
Operating Income
-$21M
+21.7% ▲
Net Income
-$32M
-32.4% ▼
EPS (Diluted)
$-1.77
+44.8% ▲
EBITDA
-$17M
+29.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $102M | $81M | $63M | $57M | $62M |
| YoY Growth | +12.8% | -20.4% | -23.0% | -9.1% | +8.3% |
| Cost of Revenue | $53M | $55M | $53M | $37M | $40M |
| Gross Profit | $49M | $33M | $22M | $19M | $21M |
| Gross Margin | 47.6% | 41.2% | 35.3% | 34.2% | 34.8% |
| R&D Expenses | $5M | $4M | $4M | $4M | $5M |
| SG&A Expenses | $25M | $25M | $29M | $31M | $29M |
| Operating Expenses | $48M | $30M | $33M | $46M | $43M |
| Operating Income | $82K | $4M | -$15M | -$27M | -$21M |
| Operating Margin | 0.1% | 4.9% | -24.4% | -47.6% | -34.4% |
| Interest Expense | $7M | $7M | $25M | $10M | $10M |
| Income Before Tax | -$7M | -$2M | -$44M | -$37M | -$31M |
| Tax Expense | -$620K | -$74K | -$194K | -$59K | $486K |
| Net Income | -$6M | $875K | -$41M | -$24M | -$32M |
| Net Margin | -6.3% | 1.1% | -65.6% | -42.3% | -51.6% |
| EPS (Diluted) | $-1.54 | $0.16 | $-5.20 | $-3.20 | $-1.77 |
| EBITDA | $3M | $11M | -$17M | -$24M | -$17M |
| Shares Outstanding | 4M | 5M | 8M | 8M | 18M |